Oxford Science Enterprises

Porpoise Power develops a tidal energy system using oscillating hydrofoil technology inspired by dolphin swimming mechanics.

Mode Labs provide robust, continuous, and remote real-time chemical sensors.

Seloxium is a company focused on assisting mining, refining, and industrial sectors in achieving their environmental, social, and governance (ESG) objectives by transforming wastewater into profitable and sustainable resources. Utilizing advanced selective flocculation technology, Seloxium enables the extraction of valuable metals from wastewater and mine tailings, offering an innovative approach to metal recovery. This technology allows businesses to obtain high-purity metals from their waste streams while minimizing their carbon footprint and preventing harmful metals from entering the environment. By providing an effective solution for recycling and refining processes, Seloxium supports companies in enhancing their sustainability practices and improving their overall environmental impact.

Alloyed is a company based in Begbroke, United Kingdom, founded in 2017, that specializes in the research and development of alloy design methods and advanced materials. The firm focuses on creating proprietary software, specifically Alloys-by-Design, which allows for rapid alloy design and optimization. This software employs data and advanced physical models to simulate the performance of various alloys, enabling the evaluation of millions of potential alloy combinations across a wide range of applications. Alloyed serves multiple industries, including aerospace, automotive, defense, medical devices, energy, and consumer goods, providing tailored solutions that enhance performance and efficiency in alloy production and application.

Mixergy Ltd, founded in 2014 and based in Cassington, United Kingdom, specializes in the development of energy storage equipment, particularly hot water tanks. The company aims to provide cost-effective solutions that enhance energy efficiency and support the integration of renewable energy sources. By optimizing the use of solar photovoltaic systems and heat pumps, Mixergy tanks contribute to grid balancing, promoting greater utilization of renewable power generation.

Salience Labs specializes in developing hybrid photonic-electronic chips tailored for artificial intelligence applications. Originating from extensive research at the University of Oxford and the University of Münster, the company focuses on silicon photonics to meet the increasing demands of AI workloads in data center infrastructure. Its flagship product, an optical switch, enables all-optical networking between computing nodes, effectively addressing data movement bottlenecks. By utilizing photons instead of electrons for data processing, Salience Labs' technology significantly reduces power consumption while enhancing processing speeds. This innovative approach aims to transform the hardware landscape necessary for maximizing AI capabilities, providing low-latency, high-bandwidth networking that accelerates job completion and lowers operational costs.

Neu Health develops a smartphone-based clinical platform designed to deliver personalized care for individuals with Parkinson's disease and dementia. Utilizing cutting-edge digital technologies and artificial intelligence, the platform monitors and interprets digital indicators of clinically relevant symptoms. This approach aims to enhance condition management, alleviate the workload on clinicians, and ultimately improve patient outcomes. By enabling clinicians and caregivers to provide more efficient and effective care, Neu Health addresses the growing challenges faced by those managing these complex neurological conditions.

FluoRok is transforming the production of fluorochemicals with its innovative technology that prioritizes safety, sustainability, and cost-effectiveness. The company has developed a patented process that eliminates the use of hazardous hydrofluoric acid, providing a cleaner alternative for industries such as agrochemicals, pharmaceuticals, and materials. By offering a safer means of accessing fluorochemicals, FluoRok aims to support a more sustainable future while enabling businesses to meet their production needs without compromising safety or environmental standards.

Iota Sciences Ltd. is a company based in Oxford, United Kingdom, founded in 2016. It specializes in developing and delivering innovative tools and technologies that utilize fluid shaping technologies to enhance drug discovery processes. The company focuses on creating fluidic mu-wells specifically designed for cell biology applications, aiming to advance research and discovery in this field. Through its unique capabilities, Iota Sciences seeks to facilitate significant advancements in the understanding and manipulation of cellular systems.

PQShield Ltd specializes in post-quantum cryptographic solutions aimed at securing technology infrastructures against potential threats posed by quantum computing. Founded in 2018 and based in Oxford, United Kingdom, the company develops a range of products including PQSoC, a toolkit for post-quantum system on chip crypto co-processors, PQSDK, which integrates post-quantum primitives with the OpenSSL API, and PQE2E, a software development toolkit designed for secure data in transit messaging. PQShield's innovations help businesses transition from traditional cryptographic standards to quantum-secure alternatives, ensuring the protection of sensitive data and communications. The company is actively involved in standardization efforts globally, advancing cybersecurity practices in the face of evolving technological challenges.

Fractile is building chips to run large language models two orders of magnitude faster. Existing hardware is good for training LLMs, but very poorly suited to subsequent inference of the trained model, which is increasingly the dominant workload. A network’s weights need to be moved onto a chip once per word generated, and this movement takes a few hundred times longer than the subsequent computations themselves. Fractile’s revolutionary approach to fusing computation with memory eliminates this bottleneck, and can scale to allow running the world’s largest models at a global scale.

Amber Therapeutics develops the next-generation of bioelectrical therapies that can sense and adapt as well as stimulate, with the potential to radically improve clinical outcomes in patients with functional disorders of the peripheral nervous system.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.

Oxford Quantum Circuits specializes in quantum computing technology that aims to address significant global challenges, such as climate change and drug discovery. The company has developed a fully functional quantum computer that integrates control systems, hardware, and software, enabling customers to streamline operations and explore innovative solutions. Their unique superconducting circuits are designed to maintain high qubit quality and control, which is essential for achieving commercially viable processing power. By leveraging this advanced technology, Oxford Quantum Circuits supports a range of applications, from pioneering new battery technologies to facilitating life-changing discoveries in medicine.

Sitryx Therapeutics is a biopharmaceutical company founded in 2018 and headquartered in Oxford, United Kingdom. The company focuses on developing innovative disease-modifying therapeutics in the fields of immuno-oncology and immuno-inflammation by regulating cell metabolism. Sitryx aims to enhance immune cell functions to inhibit tumor growth and improve immune responses. Co-founded by leading scientists from the United States and Europe, the company has attracted significant investment, including $30 million in Series A funding from a consortium of specialist investors. Sitryx has established a diverse pipeline of projects at various stages of drug discovery, positioning itself at the forefront of immunometabolism research.

Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.

Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.

Prolific operates an online platform that facilitates the recruitment of survey participants, enabling researchers to gather high-quality psychological and behavioral data quickly and ethically. By connecting diverse individuals from around the globe, Prolific enhances the efficiency of data collection and ensures that users can find suitable participants for their studies on demand. The platform allows users to specify their target audience and rewards participants for their involvement, thereby promoting engagement and reliability in research efforts. Prolific's mission focuses on making trustworthy data more accessible, ultimately contributing to improved human knowledge and informed decision-making.

Beacon Therapeutics is a clinical-stage biotechnology company that specializes in ophthalmic gene therapy aimed at restoring and improving vision for patients with rare retinal diseases that can lead to blindness. Utilizing a proprietary gene therapy platform, the company develops innovative genetic therapies tailored for individuals suffering from rare and debilitating conditions, particularly in the fields of ophthalmology and pulmonary medicine. Through its work, Beacon Therapeutics seeks to transform the lives of patients facing severe health challenges by offering potential breakthrough treatments.

Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

Mixergy Ltd, founded in 2014 and based in Cassington, United Kingdom, specializes in the development of energy storage equipment, particularly hot water tanks. The company aims to provide cost-effective solutions that enhance energy efficiency and support the integration of renewable energy sources. By optimizing the use of solar photovoltaic systems and heat pumps, Mixergy tanks contribute to grid balancing, promoting greater utilization of renewable power generation.

QuantrolOx specializes in developing automated machine learning-based control software for quantum technologies, focusing on the tuning, stabilization, and optimization of qubits. By providing robust software solutions, the company aids quantum scientists in achieving stable platforms for experimentation, which enhances the effectiveness of quantum computing applications. This innovative approach allows clients to utilize more cost-effective quantum infrastructure while efficiently implementing standard quantum computing technologies in their operations.

Mind Foundry Limited, headquartered in Oxford, United Kingdom, was founded in 2015 and specializes in developing software that helps organizations extract valuable insights from their data. As a spin-off from Oxford University, Mind Foundry combines innovation with usability through its Responsible AI platform, which addresses significant real-world challenges across various sectors, including insurance, infrastructure, and defense. The company’s technologies apply machine learning and advanced algorithmic modeling to enhance decision-making and problem-solving capabilities for clients. Founded by noted AI and machine learning experts, Mind Foundry aims to foster collaboration between humans and AI, promoting responsible and transparent AI usage while tackling pressing issues such as insurance fraud detection and complex signal processing.

Quantum Motion Technologies is focused on developing universal quantum computers utilizing silicon-based, CMOS-compatible processes. The company aims to address key challenges in quantum computing, such as fault tolerance and qubit redundancy, by creating scalable architectural technologies. By leveraging complementary metal-oxide semiconductor processing, Quantum Motion strives to achieve greater qubit density, enabling the construction of large-scale quantum systems. This approach not only enhances the performance of quantum computers but also assists clients in the quantum technology sector in overcoming significant errors and critical challenges in quantum information processing.

Archangel Lightworks is a company specializing in laser communications technology aimed at enhancing space-ground connectivity. By developing secure, wireless systems that utilize laser transmission, the company addresses the limitations of traditional radio communications, which are often bandwidth-constrained and lack security. Archangel Lightworks produces a range of products, including space terminals for satellites, air terminals for drones and manned aircraft, and ground communication terminals. These innovations provide the aerospace sector with resilient connectivity solutions, paving the way for the future of space-enabled networks.

Grey Wolf Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on developing innovative immunotherapies for oncology. Founded in 2017, the company aims to enhance the visibility of non-responsive tumors to the immune system by directly modifying tumor cells. Its approach involves targeting endoplasmic reticulum aminopeptidases (ERAP) 1 and 2 within the antigen presentation pathway, which increases the neoantigen repertoire on tumor cells. This strategy is designed to improve the effectiveness of immunotherapy in treating cancer. Grey Wolf collaborates with leading academic and commercial partners to advance its drug discovery initiatives and deliver clinical candidates against well-validated targets in the field of immuno-oncology.

Amber Therapeutics develops the next-generation of bioelectrical therapies that can sense and adapt as well as stimulate, with the potential to radically improve clinical outcomes in patients with functional disorders of the peripheral nervous system.

Oxford Ionics is a quantum computing startup focused on advancing the development of reliable quantum computers through its innovative use of trapped-ion technology. By combining high-performance qubits with noiseless electronic qubit control, the company offers solutions that allow for precise manipulation of qubits with minimal noise. This technology supports the creation of scalable quantum chips using standard semiconductor fabrication methods, which enhances efficiency and facilitates significant progress in the quantum computing market. Clients benefit from improved computational capabilities, enabling them to tackle complex problem-solving tasks more effectively.

BehaVR, LLC is a healthcare technology company founded in 2016 and based in Elizabethtown, Kentucky. The company specializes in developing digital therapeutics that leverage virtual reality to address behavioral health challenges, particularly in the context of chronic diseases. BehaVR's platform aims to enhance skills such as stress resilience, emotional regulation, and self-efficacy, enabling individuals to better manage their conditions, adhere to treatment plans, and ultimately improve their overall health outcomes. Through its innovative approach, BehaVR seeks to bridge the gap between behavioral health and chronic disease management.

Osler Diagnostics is a UK-based company focused on providing accessible health diagnostics. Established in 2017 from research at the University of Oxford, Osler has developed the Osler Origin, a portable laboratory capable of delivering lab-quality diagnostics anywhere, anytime. This innovative device requires only a drop of blood to test for a wide range of biomarkers, allowing users to monitor various health markers conveniently. Osler aims to serve diverse healthcare settings globally, empowering individuals to understand and manage their health more effectively. The company is headquartered in Oxford, UK.

Util is a developer of sustainability intelligence technology that provides investors with an objective, evidence-based assessment of a company's impact. By leveraging big data and machine learning, Util aggregates and analyzes comprehensive company data related to various stakeholders, including employees, customers, and the environment. This information is transformed into a dollar-based annual value generated metric, enabling responsible investors to evaluate both financial and non-financial returns. The company's innovative methodology goes beyond traditional ESG metrics, portraying companies as complex value generators. Util's product encompasses all listed securities and is specifically designed for investment managers seeking advanced analysis that aligns with the efficiencies of financial reporting. Currently, Util collaborates with two investment manager partners who collectively manage $130 billion in assets to refine its methodology and product offerings.

Nucleome Therapeutics is a biotechnology company based in Oxford, United Kingdom, focused on transforming drug discovery by decoding the complexities of the human genome. Founded in 2019, the company utilizes a unique genomics platform that leverages the three-dimensional structure of the genome and machine learning to explore the vast, largely uncharted regions of the genome, often referred to as the dark matter. This area contains over 95% of disease-linked genetic variants, providing significant opportunities for identifying new therapeutic targets. Nucleome Therapeutics specializes in creating high-resolution genome structure maps and validating genetic variants in primary cell types, facilitating the discovery and development of novel precision medicines. The company's initial emphasis is on lymphocytes and autoimmune diseases, with the goal of establishing a robust pipeline of drug candidates and corresponding biomarkers. Founded by experts in gene regulation from the University of Oxford, Nucleome is backed by investments from Oxford Sciences Innovation.

Opsydia Limited specializes in innovative laser marking technology that enables the creation of invisible structures within transparent materials. Founded in 2017 and based in Begbroke, United Kingdom, the company’s technology allows for the permanent and inimitable marking of serial numbers, images, and cryptographic data without altering the surface or compromising the integrity of materials like diamonds, glass, and polymers. This capability positions Opsydia to significantly enhance security and authenticity in various industries, particularly in diamond trading where identity verification is crucial. By embedding marks that are not visible to the naked eye, Opsydia's solutions provide a unique advantage in safeguarding valuable assets and improving overall material quality.

Oxford Quantum Circuits specializes in quantum computing technology that aims to address significant global challenges, such as climate change and drug discovery. The company has developed a fully functional quantum computer that integrates control systems, hardware, and software, enabling customers to streamline operations and explore innovative solutions. Their unique superconducting circuits are designed to maintain high qubit quality and control, which is essential for achieving commercially viable processing power. By leveraging this advanced technology, Oxford Quantum Circuits supports a range of applications, from pioneering new battery technologies to facilitating life-changing discoveries in medicine.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.

ORCA Computing Limited, founded in 2019 and located in Oxford, United Kingdom, specializes in the development of quantum computers utilizing photonic technology. The company is focused on creating scalable and flexible quantum computing systems powered by quantum memories, which enhance the storage and synchronization of quantum operations. By combining proprietary memory technology with standard telecom and optical fiber components, ORCA Computing offers a novel modular architecture that leverages the full potential of photonic computing. This innovative approach aims to unlock advanced applications across various industries, accelerate technological innovation, and significantly improve performance in quantum computing.

BibliU Ltd is a software company headquartered in London, UK, with an additional office in New York, that specializes in providing a digital platform for accessing textbooks and educational resources. Founded in 2014, BibliU enables students to access textbooks and other course materials online through various devices, allowing for flexible study options. The company's platform offers features such as offline support, a discovery search tool, and tools for synchronized highlights and comments, enhancing the learning experience and productivity. BibliU collaborates with numerous publishers and open educational resource providers to offer a vast array of digital content, making academic materials more accessible and affordable for colleges and universities.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was incorporated in 2017. It was spun out from the University of Oxford and focuses on developing innovative agricultural technologies aimed at enabling farmers to produce healthy food through sustainable crop systems. The company leverages research led by Professor Liam Dolan to discover new methods that enhance agricultural productivity while promoting sustainability.

Salience Labs specializes in developing hybrid photonic-electronic chips tailored for artificial intelligence applications. Originating from extensive research at the University of Oxford and the University of Münster, the company focuses on silicon photonics to meet the increasing demands of AI workloads in data center infrastructure. Its flagship product, an optical switch, enables all-optical networking between computing nodes, effectively addressing data movement bottlenecks. By utilizing photons instead of electrons for data processing, Salience Labs' technology significantly reduces power consumption while enhancing processing speeds. This innovative approach aims to transform the hardware landscape necessary for maximizing AI capabilities, providing low-latency, high-bandwidth networking that accelerates job completion and lowers operational costs.

OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

Scenic Biotech is a biotechnology company focused on developing innovative genomics and immunotherapy technologies aimed at addressing severe diseases, including cancer and rare genetic disorders. The company's approach involves identifying genetic suppressors, which are genes that can counteract the effects of disease-causing mutations, thus serving as new drug targets. By leveraging its advanced technology, Scenic Biotech enables scientists to rapidly identify and validate these novel drug targets, facilitating the development of disease-modifying therapeutics. This targeted strategy not only enhances the understanding of genetic influences on diseases but also aims to improve treatment outcomes for affected patients.

First Light Fusion Limited, founded in 2011 and based in Begbroke, United Kingdom, specializes in advanced implosion processes for electricity generation through inertial confinement fusion. The company originated as a spin-out from the University of Oxford and actively engages in researching and developing sustainable renewable energy solutions. It employs a team of engineers and physicists and collaborates with several academic institutions, including the University of Oxford, Warwick University, UCL, and Imperial College London. First Light Fusion focuses on harnessing fundamental physics to discover new energy sources, utilizing detailed numerical simulations and experimental validation in its research efforts.

PQShield Ltd specializes in post-quantum cryptographic solutions aimed at securing technology infrastructures against potential threats posed by quantum computing. Founded in 2018 and based in Oxford, United Kingdom, the company develops a range of products including PQSoC, a toolkit for post-quantum system on chip crypto co-processors, PQSDK, which integrates post-quantum primitives with the OpenSSL API, and PQE2E, a software development toolkit designed for secure data in transit messaging. PQShield's innovations help businesses transition from traditional cryptographic standards to quantum-secure alternatives, ensuring the protection of sensitive data and communications. The company is actively involved in standardization efforts globally, advancing cybersecurity practices in the face of evolving technological challenges.

Animal Dynamics is a company focused on developing advanced robotics inspired by the principles of evolutionary biomechanics. By leveraging recent advancements in analytical technology, the company evaluates high-performance animals to understand the mechanisms behind their efficiency and effectiveness. Animal Dynamics integrates fine engineering with a deep comprehension of these natural designs to create innovative robotic systems. Their platform combines insights from nature with cutting-edge materials science, microelectronics, and software engineering, resulting in a new generation of robotic vehicles. These vehicles have applications in various sectors, including agriculture for crop spraying and surveying, as well as in humanitarian aid, fire suppression, and military logistics. The company's mission emphasizes not only performance beyond current engineering capabilities but also a commitment to environmental protection through inspiration drawn from nature.

natcap is a nature intelligence company that provides report and act on impacts and dependencies on nature.

ONI is a leader in super-resolution microscopy, offering innovative tools that enhance biological research. The company has developed the Nanoimager, the first benchtop super-resolution microscope, which provides unprecedented usability and precision for researchers. This device enables access to various super-resolution techniques, including dSTORM, PALM, smFRET, and single-particle tracking, facilitating a deeper understanding of cellular structures and functions. ONI's products are increasingly adopted by academic researchers and pharmaceutical companies, with installations in prominent laboratories such as those at the Universities of Oxford, Cambridge, and Harvard. The company's mission is to democratize scientific discovery by making advanced imaging technology more accessible and affordable, thereby empowering researchers to visualize and share the intricate details of life. Recognized for its innovative contributions, ONI has received accolades such as being named a Disruptor to Watch and winning Best Business Start-up at the IOP Awards. Through its commitment to advancing scientific research, ONI aims to accelerate discoveries that can lead to improved health outcomes.

Alethiomics is a pre-clinical biotech company focused on developing targeted therapies for blood cancers. Utilizing advanced single-cell multi-omic technology, the company aims to discover and create innovative treatments for myeloproliferative neoplasms, which originate from mutations in cancer stem cells within the bone marrow. By leveraging this cutting-edge approach, Alethiomics seeks to provide medical professionals with effective and potentially curative therapies for patients suffering from these conditions.

Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. The company leverages artificial intelligence to create diagnostic tools that significantly improve the accuracy of echocardiography, with reported enhancements exceeding 90%. Ultromics' technology focuses on analyzing complex data from electrocardiograms, enabling healthcare providers to make informed decisions in diagnosing coronary artery disease. By providing innovative solutions for cardiologists, Ultromics aims to transform cardiovascular diagnostics and improve patient outcomes.

PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.

Rey is a membership-based, on-demand mental health company on a mission to revolutionize mental health and wellness by improving access to personalized services through technology.

Orbit Discovery Ltd. is a biotechnology company specializing in peptide display technology to discover peptide drugs for chronic diseases. Established in 2015 and based in Oxford, United Kingdom, the company utilizes an innovative in vitro bead display platform that links randomized peptide sequences to their encoding DNA. This technology enables high-throughput screening of peptides, facilitating the identification and optimization of potential drug candidates. By combining the specificity and efficacy of large biologic molecules with the advantages of small molecules, such as lower manufacturing costs and simpler delivery methods, Orbit Discovery aims to address a wide range of chronic diseases affecting large patient populations. The company's focus is on both internal drug discovery programs and collaborative research efforts, streamlining the discovery process and accelerating the development of new peptide therapeutics.

Omega Crop specializes in advanced crop modeling and remote-sensing technology to enhance agricultural performance. By integrating geostatistics with a comprehensive data ecosystem, Omega Crop forecasts crop performance risks and assists farmers in making informed decisions. Their innovative approach combines various data sources, including satellites, drones, mobile devices, and localized weather information, to deliver detailed assessments of farming operations. This allows growers to accurately predict yields, thereby optimizing productivity and increasing revenue. Through these technologies, Omega Crop aims to support farmers in their efforts to sustainably feed the growing global population.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunotherapeutics and vaccines aimed at treating and preventing infectious diseases and cancer. The company utilizes proprietary modified simian adenoviral vectors, specifically ChAdOx1 and ChAdOx2, along with the Modified Vaccinia Ankara (MVA) boost vector, both of which are designed to be safe and non-replicative in humans. This combination approach has demonstrated the ability to generate significantly higher levels of CD8+ T cells compared to other methodologies. Barinthus Biotherapeutics maintains a diverse pipeline that includes both clinical and preclinical therapeutic programs targeting solid tumors, viral infections, and prophylactic viral vaccines. In collaboration with the University of Oxford, the company co-invented a COVID-19 vaccine that has received approval for use in various regions worldwide.

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.

SpyBiotech Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in the development of innovative vaccines using a proprietary technology known as molecular superglue. This platform allows for the rapid creation of bonding vaccines by attaching antigens to viruses and other particles, enhancing the vaccine development process. By leveraging this unique approach, SpyBiotech aims to provide medical institutions and research centers with more effective vaccines that can be developed in a shorter timeframe, ultimately improving immunity against various diseases, including bacterial infections.

Theolytics Limited is a clinical-stage biotechnology company founded in 2017 and based in Oxford, United Kingdom. The company specializes in developing oncolytic viral therapies to combat cancer, utilizing a phenotypic screening platform that facilitates the discovery and development of effective, targeted treatment candidates. These therapies are designed for intravenous delivery and tailored to specific patient populations, aiming to provide innovative care options. In addition to advancing its internal pipeline of programs that address both solid and liquid tumors, Theolytics is also focused on forming strategic partnerships to enhance and expedite its pipeline development.

Living Optics Limited, founded in 2019 and based in Oxford, United Kingdom, specializes in the design and development of compact hyperspectral imaging cameras and related software. The company's innovative technology captures data that is not visible to the human eye or traditional cameras, making hyperspectral imaging more accessible and affordable for a variety of applications in consumer products, medical devices, and the manufacturing industry. Living Optics aims to empower computer vision developers and scientists by providing portable solutions that enable the integration of spectral imaging data into new research and applications. In September 2022, the company secured $25 million in Series A funding to further its mission of revolutionizing the imaging market.

DJS Antibodies Ltd, founded in 2014 and based in Bicester, United Kingdom, focuses on the design and discovery of novel therapeutic monoclonal antibodies targeting G-protein-coupled receptors (GPCRs). The company specializes in developing innovative therapeutics aimed at treating chronic inflammatory diseases, utilizing breakthrough technology to create first-in-class antibodies against challenging disease targets. By isolating high-quality antibodies against complex protein targets that have previously proven difficult for drug discovery, DJS Antibodies aims to provide effective treatments for conditions that are currently undruggable and untreatable.

T-Cypher Bio is an early-stage biotechnology company focused on developing T-cell receptor (TCR)-based therapeutics aimed at treating solid tumors as well as autoimmune, inflammatory, and infectious diseases. The company addresses the challenges associated with identifying therapeutically relevant targets and TCRs through its integrated platform, D-Cypher. This platform employs advanced techniques to generate target screening libraries, enabling the identification of functionally defined T-cell clones directly from disease tissues. By offering an end-to-end approach to cell therapy development and patient treatment, T-Cypher Bio aims to provide innovative solutions that could significantly enhance cancer care and address various health conditions.

PepGen is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing nucleic acid therapeutics, particularly antisense oligonucleotides. Founded in 2018, the company aims to enhance the delivery and efficacy of these therapies through its proprietary Enhanced Delivery Oligonucleotide (EDO) platform. This innovative platform utilizes engineered peptides designed to improve tissue penetration, cellular uptake, and nuclear delivery of oligonucleotides. PepGen's technology has shown promise in preclinical studies, demonstrating the ability to transport therapeutics effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. The company's mission is to unlock the full potential of nucleic acid therapeutics to transform the treatment landscape for severe neuromuscular and neurological diseases.

Refeyn Ltd, founded in 2018 and based in Oxford, United Kingdom, specializes in mass photometry technology for the analysis of biomolecules. The company's flagship product, Refeyn One, employs single molecule light scattering to detect, image, and accurately determine the mass of biomolecules in solution. This innovative optical technology allows researchers to measure the mass of individual molecules in their native state without the necessity for labels, providing both quality-control instruments and advanced research tools. Refeyn's offerings enable scientists to conduct mass measurements across a range of biologically relevant concentrations, enhancing the capabilities of biomolecular analysis.

ORCA Computing Limited, founded in 2019 and located in Oxford, United Kingdom, specializes in the development of quantum computers utilizing photonic technology. The company is focused on creating scalable and flexible quantum computing systems powered by quantum memories, which enhance the storage and synchronization of quantum operations. By combining proprietary memory technology with standard telecom and optical fiber components, ORCA Computing offers a novel modular architecture that leverages the full potential of photonic computing. This innovative approach aims to unlock advanced applications across various industries, accelerate technological innovation, and significantly improve performance in quantum computing.

PQShield Ltd specializes in post-quantum cryptographic solutions aimed at securing technology infrastructures against potential threats posed by quantum computing. Founded in 2018 and based in Oxford, United Kingdom, the company develops a range of products including PQSoC, a toolkit for post-quantum system on chip crypto co-processors, PQSDK, which integrates post-quantum primitives with the OpenSSL API, and PQE2E, a software development toolkit designed for secure data in transit messaging. PQShield's innovations help businesses transition from traditional cryptographic standards to quantum-secure alternatives, ensuring the protection of sensitive data and communications. The company is actively involved in standardization efforts globally, advancing cybersecurity practices in the face of evolving technological challenges.

Oxford Ionics is a quantum computing startup focused on advancing the development of reliable quantum computers through its innovative use of trapped-ion technology. By combining high-performance qubits with noiseless electronic qubit control, the company offers solutions that allow for precise manipulation of qubits with minimal noise. This technology supports the creation of scalable quantum chips using standard semiconductor fabrication methods, which enhances efficiency and facilitates significant progress in the quantum computing market. Clients benefit from improved computational capabilities, enabling them to tackle complex problem-solving tasks more effectively.

Base Genomics Limited is an epigenetics company focused on advancing DNA methylation technology through its innovative TAPS (TET-assisted pyridine borane sequencing) method. Developed at the Ludwig Institute for Cancer Research at the University of Oxford, TAPS allows for the simultaneous generation of genetic and epigenetic information at base resolution. This technology addresses the limitations of traditional bisulfite sequencing by preserving DNA integrity, thus providing more high-quality data from smaller samples. Base Genomics targets various significant markets, including early cancer detection, minimal residual disease analysis, patient monitoring, and non-invasive prenatal testing. The company aims to enhance medical practices by offering reliable and efficient methods for cancer detection and monitoring, ultimately transforming patient outcomes. Base Genomics was founded in 2019 and is based in Oxford, United Kingdom.

Oxford Flow Ltd. is a company that designs, manufactures, and supplies pressure control equipment, including gas regulators, water pressure reducing valves (PRVs), silencers, and pilots. Established in 2015 and based in Oxford, United Kingdom, the company serves a variety of industries such as water, gas, marine, oil and gas, process, power, and building services. Oxford Flow's products are engineered to simplify systems and enhance reliability while meeting rigorous standards for water quality and leakage control. The company focuses on delivering practical solutions that improve operational efficiency and reduce environmental impact, backed by extensive testing and customer feedback. By combining academic expertise with industry knowledge, Oxford Flow aims to provide innovative and efficient pressure control solutions that help customers save costs without compromising performance.

Navenio Limited is a software technology company based in Oxford, United Kingdom, that specializes in location-based services for indoor environments. Founded in 2015, Navenio offers a mobile application solution that enhances indoor localization by enabling the tracking of individuals without the need for additional hardware, such as beacons or Wi-Fi. This innovative approach utilizes fingerprinting of the electromagnetic spectrum, sensor data, and indoor mapping to provide accurate location monitoring across various sectors, including retail, transportation, venues, and healthcare. Navenio's intelligent workforce solution significantly improves operational efficiency and workflow by automating processes based on real-world best practices.

Quantum Motion Technologies is focused on developing universal quantum computers utilizing silicon-based, CMOS-compatible processes. The company aims to address key challenges in quantum computing, such as fault tolerance and qubit redundancy, by creating scalable architectural technologies. By leveraging complementary metal-oxide semiconductor processing, Quantum Motion strives to achieve greater qubit density, enabling the construction of large-scale quantum systems. This approach not only enhances the performance of quantum computers but also assists clients in the quantum technology sector in overcoming significant errors and critical challenges in quantum information processing.

BibliU Ltd is a software company headquartered in London, UK, with an additional office in New York, that specializes in providing a digital platform for accessing textbooks and educational resources. Founded in 2014, BibliU enables students to access textbooks and other course materials online through various devices, allowing for flexible study options. The company's platform offers features such as offline support, a discovery search tool, and tools for synchronized highlights and comments, enhancing the learning experience and productivity. BibliU collaborates with numerous publishers and open educational resource providers to offer a vast array of digital content, making academic materials more accessible and affordable for colleges and universities.

Living Optics Limited, founded in 2019 and based in Oxford, United Kingdom, specializes in the design and development of compact hyperspectral imaging cameras and related software. The company's innovative technology captures data that is not visible to the human eye or traditional cameras, making hyperspectral imaging more accessible and affordable for a variety of applications in consumer products, medical devices, and the manufacturing industry. Living Optics aims to empower computer vision developers and scientists by providing portable solutions that enable the integration of spectral imaging data into new research and applications. In September 2022, the company secured $25 million in Series A funding to further its mission of revolutionizing the imaging market.

Perspectum is a global medical technology company that focuses on improving care for patients with liver disease, diabetes, and cancer. By utilizing advanced imaging and genetics, the company emphasizes precision medicine to enhance early detection, diagnosis, and targeted treatment of complex health issues. Perspectum's diverse team, which includes physicians, biomedical scientists, engineers, and technologists, works collaboratively to develop innovative digital technologies. Their aim is to empower both patients and clinicians by providing quantitative health assessments, enabling more effective management of metabolic diseases and multi-organ pathology.

Animal Dynamics is a company focused on developing advanced robotics inspired by the principles of evolutionary biomechanics. By leveraging recent advancements in analytical technology, the company evaluates high-performance animals to understand the mechanisms behind their efficiency and effectiveness. Animal Dynamics integrates fine engineering with a deep comprehension of these natural designs to create innovative robotic systems. Their platform combines insights from nature with cutting-edge materials science, microelectronics, and software engineering, resulting in a new generation of robotic vehicles. These vehicles have applications in various sectors, including agriculture for crop spraying and surveying, as well as in humanitarian aid, fire suppression, and military logistics. The company's mission emphasizes not only performance beyond current engineering capabilities but also a commitment to environmental protection through inspiration drawn from nature.

OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

Oxford VR Limited specializes in developing cognitive treatments for various clinical conditions using virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, the company leverages extensive research from Professor Daniel Freeman to create automated therapies delivered by a virtual coach. These innovative treatments address issues such as fear of heights, psychosis, and social anxiety. By utilizing immersive VR experiences, Oxford VR aims to provide faster, more effective, and cost-efficient psychological interventions compared to traditional methods. The company's focus is on delivering clinically validated and user-centered solutions that enhance access to mental health care, benefiting patients, healthcare professionals, and the broader health system.

Alloyed is a company based in Begbroke, United Kingdom, founded in 2017, that specializes in the research and development of alloy design methods and advanced materials. The firm focuses on creating proprietary software, specifically Alloys-by-Design, which allows for rapid alloy design and optimization. This software employs data and advanced physical models to simulate the performance of various alloys, enabling the evaluation of millions of potential alloy combinations across a wide range of applications. Alloyed serves multiple industries, including aerospace, automotive, defense, medical devices, energy, and consumer goods, providing tailored solutions that enhance performance and efficiency in alloy production and application.

Mixergy Ltd, founded in 2014 and based in Cassington, United Kingdom, specializes in the development of energy storage equipment, particularly hot water tanks. The company aims to provide cost-effective solutions that enhance energy efficiency and support the integration of renewable energy sources. By optimizing the use of solar photovoltaic systems and heat pumps, Mixergy tanks contribute to grid balancing, promoting greater utilization of renewable power generation.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on developing antibody modulators for immune cell receptors aimed at treating autoimmune diseases. Founded in 2018, MiroBio leverages pioneering research from the University of Oxford to understand how immune cells communicate and are activated. This foundational knowledge allows the company to create innovative antibodies that stimulate specific immune cell signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural pathways, MiroBio's therapeutics aim to provide significant benefits to patients suffering from various autoimmune conditions, enabling clinicians to effectively manage overactive immune responses associated with these diseases.

YASA Motors Ltd. specializes in the manufacture of axial flux motors and generators tailored for electric and hybrid vehicles, as well as for various industrial applications. Established in 2009, the company produces a range of electric motors, including low-speed high-torque models and those designed for higher speed and power applications. YASA's innovative motor technology is particularly suited for sectors such as automotive, aerospace, marine, and construction equipment, where it addresses needs for traction, propulsion, and power generation. In addition to standard products, YASA offers custom motor solutions and consultancy services, which encompass electrical architecture design and thermal modeling. The company operates from its headquarters in Yarnton, United Kingdom, where it focuses on developing efficient, lightweight motors that meet the increasing global demand for reduced emissions and improved energy efficiency across multiple industries.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was incorporated in 2017. It was spun out from the University of Oxford and focuses on developing innovative agricultural technologies aimed at enabling farmers to produce healthy food through sustainable crop systems. The company leverages research led by Professor Liam Dolan to discover new methods that enhance agricultural productivity while promoting sustainability.

Zegami Limited is a company that specializes in visual data exploration tools designed for the analysis of large collections of images, particularly in scientific and medical contexts. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami transforms visual data into actionable information by integrating media, data, and artificial intelligence. Its platform supports users in searching, sorting, filtering, and grouping data, which facilitates the identification of patterns, correlations, and anomalies. The solution caters to a variety of sectors, including heating, ventilation, and air conditioning (HVAC) management, microscopy, genomics, and cultural heritage organizations such as galleries and museums. Additionally, Zegami offers a plugin API that enables developers to create custom visualizations, enhancing the platform's versatility and applicability across different fields.

Zegami Limited is a company that specializes in visual data exploration tools designed for the analysis of large collections of images, particularly in scientific and medical contexts. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami transforms visual data into actionable information by integrating media, data, and artificial intelligence. Its platform supports users in searching, sorting, filtering, and grouping data, which facilitates the identification of patterns, correlations, and anomalies. The solution caters to a variety of sectors, including heating, ventilation, and air conditioning (HVAC) management, microscopy, genomics, and cultural heritage organizations such as galleries and museums. Additionally, Zegami offers a plugin API that enables developers to create custom visualizations, enhancing the platform's versatility and applicability across different fields.

Oxford Semantic Technologies is a company focused on developing RDFox, a high-performance knowledge graph and semantic reasoning engine designed to leverage modern multi-core architecture. Founded in 2017 as a spin-out from the University of Oxford, the company aims to translate advanced research in semantic web technologies into practical industrial applications. The RDFox engine, which started development in 2011, employs patented computing techniques that allow for the rapid processing of complex queries, significantly reducing the need for IT expertise. This capability enables domain experts to formulate their own queries, streamline development cycles for data analysis, and validate results through detailed explanations of how answers are derived from the underlying data. Oxford Semantic Technologies has positioned itself as a key player in unlocking innovative enterprise applications for its clients.

Albus Health, a startup emerging from the University of Oxford, has created an intelligent nocturnal monitoring platform designed for personalized home use. This system facilitates passive, contactless, and objective monitoring of various symptoms and environmental metrics, making it particularly useful for assessing nocturnal conditions. The platform has been successfully commercialized and is currently employed by leading pharmaceutical companies to monitor nocturnal symptoms during clinical trials. Additionally, it has the capability to predict respiratory emergencies, thus enhancing patient safety and outcomes.

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.

Alloyed is a company based in Begbroke, United Kingdom, founded in 2017, that specializes in the research and development of alloy design methods and advanced materials. The firm focuses on creating proprietary software, specifically Alloys-by-Design, which allows for rapid alloy design and optimization. This software employs data and advanced physical models to simulate the performance of various alloys, enabling the evaluation of millions of potential alloy combinations across a wide range of applications. Alloyed serves multiple industries, including aerospace, automotive, defense, medical devices, energy, and consumer goods, providing tailored solutions that enhance performance and efficiency in alloy production and application.

Covatic Ltd, established in 2016 and headquartered in Birmingham, United Kingdom, specializes in broadcast personalization software. The company's innovative platform employs mobile-based algorithms to enhance user experience by delivering personalized content without compromising personal data. By identifying optimal engagement moments and methods for individuals, Covatic enables clients to effectively connect with their target audiences. This approach allows for the collection and personalization of insights, ultimately improving the way applications serve their users. With an emphasis on problem-solving, Covatic continues to develop solutions that enhance app functionality and user interaction.

Animal Dynamics is a company focused on developing advanced robotics inspired by the principles of evolutionary biomechanics. By leveraging recent advancements in analytical technology, the company evaluates high-performance animals to understand the mechanisms behind their efficiency and effectiveness. Animal Dynamics integrates fine engineering with a deep comprehension of these natural designs to create innovative robotic systems. Their platform combines insights from nature with cutting-edge materials science, microelectronics, and software engineering, resulting in a new generation of robotic vehicles. These vehicles have applications in various sectors, including agriculture for crop spraying and surveying, as well as in humanitarian aid, fire suppression, and military logistics. The company's mission emphasizes not only performance beyond current engineering capabilities but also a commitment to environmental protection through inspiration drawn from nature.

Caristo Diagnostics Limited, founded in 2018 as a spin-out from the University of Oxford, specializes in artificial intelligence-based software for diagnosing cardiovascular conditions. The company has developed the CaRi-Heart technology, an advanced imaging platform that enhances the prediction and diagnosis of coronary artery disease, heart attacks, strokes, and diabetes. Utilizing Cardiac Computed Tomography Angiography (CCTA), the platform measures the Fat Attenuation Index (FAI), a patented biomarker for coronary inflammation. The CaRi-Heart Report provides clinicians with critical insights, including patient-specific FAI, an assessment of the absolute 8-year risk of a fatal heart attack, and detailed characterization of coronary plaque. The technology is CE Mark certified and has received recognition in prestigious medical journals, showcasing its efficacy in predicting heart attacks. Caristo has secured over £23 million in venture capital and has been supported by various UK government grants for its innovative care pathways. With its unique combination of clinical insights and advanced technology, Caristo aims to transform cardiac care globally by improving risk prediction and prevention strategies.

Oxford VR Limited specializes in developing cognitive treatments for various clinical conditions using virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, the company leverages extensive research from Professor Daniel Freeman to create automated therapies delivered by a virtual coach. These innovative treatments address issues such as fear of heights, psychosis, and social anxiety. By utilizing immersive VR experiences, Oxford VR aims to provide faster, more effective, and cost-efficient psychological interventions compared to traditional methods. The company's focus is on delivering clinically validated and user-centered solutions that enhance access to mental health care, benefiting patients, healthcare professionals, and the broader health system.

Evox Therapeutics is a biotechnology company based in Oxford, United Kingdom, founded in 2016. The company specializes in developing exosome-based therapeutics aimed at treating rare and severe diseases. By harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, Evox focuses on creating innovative drug delivery systems that utilize nucleic acids and proteins. This technology allows for targeted delivery to specific organs, including the brain and central nervous system, addressing limitations often encountered with traditional therapies. Evox's proprietary methods for modifying exosomes enhance their ability to transport therapeutic agents effectively, thereby improving treatment options for patients with limited alternatives. The company is supported by a strong intellectual property portfolio and investments from leading life sciences venture capital groups, positioning it as a leader in the emerging field of exosome-based therapeutics.

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.